# Anika Therapeutics, Inc.: overview

ANIK · Nasdaq · CIK 898437 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/anik.md) · [Financials](/companies/anik/financials.md) · [Filings](/companies/anik/filings.md) · [Insiders](/companies/anik/insiders.md)

Latest reported revenue: [$32.6m](/filings/0001171843-26-005012.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001171843-26-005012).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [29.6](/filings/0001171843-25-007032.md) | [30.6 d](/filings/0001171843-26-001275.md) | [26.2](/filings/0001171843-26-002852.md) | [28.2](/filings/0001171843-26-005012.md) | [27.8](/filings/0001171843-25-007032.md) | [30.6 d](/filings/0001171843-26-001275.md) | [29.6](/filings/0001171843-26-002852.md) | [32.6](/filings/0001171843-26-005012.md) |
| Gross margin | % | [65.7%](/filings/0001171843-25-007032.md) | [56.0% d](/filings/0001171843-26-001275.md) | [56.1%](/filings/0001171843-26-002852.md) | [50.9%](/filings/0001171843-26-005012.md) | [56.0%](/filings/0001171843-25-007032.md) | [62.6% d](/filings/0001171843-26-001275.md) | [64.2%](/filings/0001171843-26-002852.md) | [65.1%](/filings/0001171843-26-005012.md) |
| Operating margin | % | [(0.3%)](/filings/0001171843-25-007032.md) | [(2.3%) d](/filings/0001171843-26-001275.md) | [(16.4%)](/filings/0001171843-26-002852.md) | [(14.8%)](/filings/0001171843-26-005012.md) | [(11.6%)](/filings/0001171843-25-007032.md) | [2.1% d](/filings/0001171843-26-001275.md) | [(18.5%)](/filings/0001171843-26-002852.md) | [9.1%](/filings/0001171843-26-005012.md) |
| Net margin | % | [(101.2%)](/filings/0001171843-25-007032.md) | [(71.4%) d](/filings/0001171843-26-001275.md) | [(18.6%)](/filings/0001171843-26-005012.md) | [(14.1%)](/filings/0001171843-26-005012.md) | [(8.4%)](/filings/0001171843-25-007032.md) | [1.0% d](/filings/0001171843-26-001275.md) | [(17.1%)](/filings/0001171843-26-005012.md) | [10.1%](/filings/0001171843-26-005012.md) |
| Diluted EPS | $ per share | [(2.03)](/filings/0001171843-25-007032.md) | not reported | [(0.34)](/filings/0001171843-26-002852.md) | [(0.28)](/filings/0001171843-26-005012.md) | [(0.16)](/filings/0001171843-25-007032.md) | not reported | [(0.37)](/filings/0001171843-26-002852.md) | [0.24](/filings/0001171843-26-005012.md) |
| Free cash flow | $m | [3.8 d](/filings/0001171843-25-007032.md) | [0.3 d](/filings/0001171843-26-001275.md) | [(3.0)](/filings/0001171843-26-002852.md) | [(1.7) d](/filings/0001171843-26-005012.md) | [5.0 d](/filings/0001171843-25-007032.md) | [4.0 d](/filings/0001171843-26-001275.md) | [(6.3)](/filings/0001171843-26-002852.md) | [(2.1) d](/filings/0001171843-26-005012.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [148](/filings/0001171843-24-001380.md) | [114](/filings/0001171843-25-001486.md) | [121](/filings/0001171843-26-001275.md) | [120](/filings/0001171843-26-001275.md) | [113](/filings/0001171843-26-001275.md) |
| Gross margin | % | [56.1%](/filings/0001171843-24-001380.md) | [64.3%](/filings/0001171843-25-001486.md) | [68.3%](/filings/0001171843-26-001275.md) | [63.4%](/filings/0001171843-26-001275.md) | [56.6%](/filings/0001171843-26-001275.md) |
| Operating margin | % | [1.8%](/filings/0001171843-24-001380.md) | [3.2%](/filings/0001171843-25-001486.md) | [0.7%](/filings/0001171843-26-001275.md) | [(4.3%)](/filings/0001171843-26-001275.md) | [(9.8%)](/filings/0001171843-26-001275.md) |
| Net margin | % | [2.8%](/filings/0001171843-24-001380.md) | [(13.1%)](/filings/0001171843-25-001486.md) | [(68.4%)](/filings/0001171843-26-001275.md) | [(47.0%)](/filings/0001171843-26-001275.md) | [(9.6%)](/filings/0001171843-26-001275.md) |
| Diluted EPS | $ per share | [0.28](/filings/0001171843-24-001380.md) | [(1.02)](/filings/0001171843-25-001486.md) | [(5.64)](/filings/0001171843-26-001275.md) | [(3.83)](/filings/0001171843-26-001275.md) | [(0.76)](/filings/0001171843-26-001275.md) |
| Free cash flow | $m | [3.3](/filings/0001171843-24-001380.md) | [(3.1)](/filings/0001171843-25-001486.md) | [(7.2)](/filings/0001171843-26-001275.md) | [(2.3)](/filings/0001171843-26-001275.md) | [4.4](/filings/0001171843-26-001275.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/anik/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $21.2m | 1,449,671 |  | Reduced −145,222 |
| [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $21.0m | 1,435,130 |  | Unchanged |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $9.0m | 614,320 |  | Reduced −257,746 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.4m | 572,113 |  | Reduced −33,664 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $8.2m | 559,846 |  | Added +287,577 |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $7.7m | 529,640 |  | Added +137 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $7.0m | 481,417 |  | Reduced −20,800 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $6.6m | 451,095 |  | Reduced −7,752 |
| [CAPITAL MANAGEMENT CORP /VA](/funds/1074273.md) | 2026-06-30 | $6.6m | 448,474 |  | Added +753 |
| [DEUTSCHE BANK AG\\](/funds/948046.md) | 2026-06-30 | $5.2m | 353,552 |  | Added +378 |

## Recent filings

[All 791 filings](/companies/anik/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-29 | 16:09 ET | [10-Q](/filings/0001171843-26-005012.md) | Quarterly report, period 2026-06-30 | 0001171843-26-005012 |
| 2026-07-29 | 07:20 ET | [8-K](/filings/0001171843-26-004977.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-004977 |
| 2026-07-14 | 17:00 ET | [8-K](/filings/0001171843-26-004635.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001171843-26-004635 |
| 2026-06-23 | 16:05 ET | [8-K](/filings/0001171843-26-004253.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001171843-26-004253 |
| 2026-04-30 | 19:47 ET | [10-Q](/filings/0001171843-26-002852.md) | Quarterly report, period 2026-03-31 | 0001171843-26-002852 |
| 2026-04-29 | 07:20 ET | [8-K](/filings/0001171843-26-002799.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001171843-26-002799 |
| 2026-04-28 | 16:47 ET | [DEF 14A](/filings/0001140361-26-017488.md) | Proxy statement, period 2026-06-18 | 0001140361-26-017488 |
| 2026-03-03 | 18:49 ET | [10-K](/filings/0001171843-26-001275.md) | Annual report, period 2025-12-31 | 0001171843-26-001275 |
| 2026-02-26 | 07:18 ET | [8-K](/filings/0001193125-26-073401.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-073401 |
| 2026-01-27 | 19:29 ET | [SCHEDULE 13D/A](/filings/0000902664-26-000511.md) | Ownership report, active investor, amended | 0000902664-26-000511 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001171843-26-001275.md), filed Mar 3, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6ad763db-57d0-4f56-9ef1-121aa8c1fd98)

## About the filer

- CIK: 898437
- Tickers: ANIK
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.